Patient Organization Support Agreement
This Agreement is made by and between Janssen-Cilag Af S, a company with a registered address at Hammerbakken 19, 3460 Birkerød, hereafter referred to as "Janssen"; and PROPA, Jernbanegade 23 B, Postboks 640, 4000 Roskilde, "PROPA"
hereafter referred to as
"Janssen"and "PROPA" are collectively referred to as "The Parties".
WHEREAS: "Janssen"is a research-oriented pharmaceutical company active in the development and marketing of medicinal products. PROPA has the folIowing objective: "PROPA vil gerne være med som dynamo i formidling af viden om international og national forskning og tilskynde til samarbejde med læger, politikere, myndigheder, og andre parter om at få sat fokus på sygdommen og mulighederne for behandling. " "PROPA" has asked "Janssen"to provide support for its activities in the year 2012 and "Janssen"has agreed to provide support under the terms of this agreement. THE PARTæs TO THIS AGREEMENT AGREE AS FOLLOWS:
Article 1: Support
1. For 2012 "Janssen"will provide support to "PROPA" 150.000
in the amount of DKK
2. The amount will be transferred within 2 months of the signature of this agreement on the folIowing account: Account name: Projekt: Debatmøder 2012 Account number: 5498710362 Reg: 2268 Bank name: NORDEA Bank address: Birkerød Afdeling, Hovedgade 23, 3460 Birkerød IBAN number: DK 1820005498710362 SWIFT code:
-2-
3. "PROPA" shall ensure that the support is used in a professional and ethical manner to further its purpose as described in its by-laws and consistent with this Agreement and applicable rules and legislation. "PROPA" shall inform "Janssen"on a regular basis, and at 1east two times per year or upon request, on how the support is used in general. 4. "PROPA" and "Janssen" acknowledge and agree that the support shall not obligate "PROPA" to purchase, use, recommend, or arrange for the use of any products of "Janssen". 5. "PROPA" represents and warrants that it is a tax-exempt entity under the applicable laws and that it is authorized to accept support in the form of financial contribution or other support from private companies such as "Janssen", and that, to the extent applicable, it has performed the necessary notifications or received the necessary approvals. "PROPA" will also keep "Janssen" regularly informed of its direct or indirect relationships with government officials and/or government authorities.
Article 2: Use of name and logo or other proprietary materials l. During the year 2012 "PROPA" will publicly recognize that "Janssen"provides support to "PROPA" in the following manner: Publication on the "PROPA" website.
Article 3: Transparency 1. In order to create appropriate transparency on the support to patient organization "PROPA" by "Janssen", and in line with the applicable code(s) of practice, "Jans sen" will make the existence of this agreement and details relating thereto publicly available (for example, on the internet) and "PROPA" explicitly agrees with such disclosure. More precisely, "Janssen"will make the following details publicly available: a) b) c) d) e) f)
Date that the contract was executed; Name of the patient organization: "PROPA" ; Country of the patient organization: "PROPA I Danmark" ; Web address of the patient organization"PROPA" , if available; Description of the nature and the purpose of the contribution; Amount as contracted, if financial.
In addition, "Janssen"will also make copies of this contract available to interested parties upon their request.
-32. "Janssen"is entitled to increase the level of details made publicly available either as required by applicable rules and legislation, or upon notice to "PROPA" .
Article 4: General Provisions 1. Both parties will at all times fully comply with all applicable rules and legislation, in particular anti-bribery legislation (including, but not limited to, the U.S. Foreign Corrupt Practices Act). The folIowing code(s) of conduet is(are) applicable: "UF' s etiske regler for Lægemiddelindustriens samarbejde med patientforeninger. " 2. This Agreement shall be governed by and construed under the substantive laws of Denmark without reference to the conflict of law rules. 3. In case of any dispute arising out of or in connection with this Agreement, the Parties shall first attempt (in good faith) to reach an amicable settlement. Should such amicable settlement fail, The Danish Institute of Arbitration and the Danish rules of Arbitration procedure shall have exclusive jurisdiction.
Drawn up in two (2) original copies in Birkerød on 31 st of May 2012 Both parties acknowledge having received a signed copy.
FOR "Janssen"
FOR "PROPA"
Name:
Name: ./;Ø!J1ø/W7J/J
Title:
;tøq;;~ Mikaefsjillin, M.D. Nordie MedicaI Affairs Director
Date:
Date: